PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Overview

About this study

Does pancreas enzyme replacement (PERT) decrease weight loss and improve quality of life in patients with unresectable pancreatic cancer?

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients 18-100 years
  • Underlying pancreatic adenocarcinoma, unresectable (local invasion or distant metastasis)
  • On established chemotherapy regimen for pancreas cancer, which will be continued over the time of study
  • Fecal elastase-1 test (FE1) less than 200 mcg pancreatic elastase/g stool

Exclusion Criteria:

  • Common bile duct obstruction resulting in obstructive jaundice
  • Celiac disease
  • Crohn's disease
  • Benign pancreatic conditions
  • Bowel obstruction
  • Surgically altered bowel anatomy

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions